clomiphene

  1. Tristan Loscha

    (EU) Committee for Medicinal Products for Human Use (CHMP) Assessment report: EnCyzix (Enclomifene)

    Treatment of hypogonadotropic hypogonadism (secondary hypogonadism) in adult men aged ≤60 years with a body mass index (BMI) ≥25 kg/m2 which has been confirmed by clinical features and biochemical tests in patients which have not responded to diet and exercise
Top